Alvaro L Barroso
Overview
Explore the profile of Alvaro L Barroso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosario P, Tavares W, Barroso A, Rezende L, Padrao E, Purisch S
Arq Bras Endocrinol Metabol
. 2008 Mar;
52(1):114-9.
PMID: 18345404
Computed tomography (CT or CAT Scan) of the chest is more sensitive than radiography in the detection of lung metastases of differentiated thyroid cancer (DTC), but little information is available...
2.
Rosario P, Borges M, Valadao M, Vasconcelos F, Rezende L, Padrao E, et al.
Thyroid
. 2007 Nov;
17(12):1225-8.
PMID: 18001178
To evaluate tumor recurrence after total thyroidectomy in patients with single papillary carcinoma with size <or= 2 cm and restricted to the thyroid, we studied 136 consecutive patients divided into...
3.
Rosario P, Purisch S, Vasconcelos F, Padrao E, Rezende L, Barroso A
Nucl Med Commun
. 2007 Apr;
28(6):507-8.
PMID: 17460543
No abstract available.
4.
Rosario P, Borges M, Costa G, Rezende L, Padrao E, Barroso A, et al.
Arq Bras Endocrinol Metabol
. 2007 Apr;
51(1):99-103.
PMID: 17435862
Objective: To evaluate the positive predictive value of detectable Tg during T4 therapy (Tg on T4) in patients with thyroid cancer after total thyroidectomy and remnant ablation, discussing the work-up...
5.
Rosario P, Pereira L, Padrao E, Rezende L, Barroso A, Purisch S
ANZ J Surg
. 2007 Mar;
77(4):305.
PMID: 17388843
No abstract available.
6.
Valadao M, Rosario P, Borges M, Costa G, Rezende L, Padrao E, et al.
Thyroid
. 2006 Nov;
16(11):1145-9.
PMID: 17123341
This study evaluated the positive predictive value (PPV) of detectable stimulated thyroglobulin during the first year after treatment of thyroid carcinoma (Tg-1) and the value of comparison with Tg-ablation and...
7.
Rosario P, Barroso A, Rezende L, Padrao E, Borges M, Guimaraes V, et al.
Thyroid
. 2006 Aug;
16(7):667-70.
PMID: 16889490
Our aim was to assess testicular function in patients treated with high-dose radioiodine. Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels were determined in 52 men with thyroid carcinoma...
8.
Rosario P, Vasconcelos F, Cardoso L, Lauria M, Rezende L, Padrao E, et al.
Arq Bras Endocrinol Metabol
. 2006 Apr;
50(1):91-6.
PMID: 16628280
Thyroxine (T4) withdrawal or recombinant TSH is used for the stimulation of thyroglobulin (Tg), whole-body scanning (WBS) and iodine-131 treatment in patients with thyroid carcinoma. This study evaluated the T4...
9.
Rosario P, Barroso A, Rezende L, Padrao E, Fagundes T, Reis J, et al.
Ann Nucl Med
. 2005 Jun;
19(3):247-50.
PMID: 15981681
A retrospective study was conducted on 186 patients with differentiated thyroid cancer without metastases who received an ablative dose of 100 mCi (3.7 GBq) iodine-131 after total thyroidectomy. Six months...
10.
Rosario P, Barroso A, Rezende L, Padrao E, Borges M, Fagundes T, et al.
Nucl Med Commun
. 2005 Jan;
26(2):129-32.
PMID: 15657505
Objective: To determine the success of ablative treatment using fixed high doses of 131I in patients with thyroid cancer. Methods: A retrospective study was conducted on 274 patients who received...